Tan, Wei Phin, Thomas A. Longo, and Brant A. Inman. “Heated Intravesical Chemotherapy: Biology and Clinical Utility.” Urol Clin North Am 47, no. 1 (February 2020): 55–72. https://doi.org/10.1016/j.ucl.2019.09.008.
Johnston, Ashley W., Thomas A. Longo, Leah Gerber Davis, Daniel Zapata, Stephen J. Freedland, and Jonathan C. Routh. “Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study.” Int Braz J Urol 46, no. 1 (January 2020): 42–52. https://doi.org/10.1590/S1677-5538.IBJU.2019.0225.
Tan, Wei Phin, Andrew Chang, Steven C. Brousell, Dominic C. Grimberg, Joseph J. Fantony, Thomas A. Longo, Wiguins Etienne, Ivan Spasojevic, Paolo Maccarini, and Brant A. Inman. “Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study.” Int J Hyperthermia 37, no. 1 (2020): 854–60. https://doi.org/10.1080/02656736.2020.1780328.
Gopalakrishna, Ajay, Andrew Chang, Thomas A. Longo, Joseph J. Fantony, Michael R. Harrison, Paul E. Wischmeyer, and Brant A. Inman. “Dietary patterns and health-related quality of life in bladder cancer survivors.” Urol Oncol 36, no. 10 (October 2018): 469.e21-469.e29. https://doi.org/10.1016/j.urolonc.2018.06.001.
Qi, Robert, Wen-Chi Foo, Michael N. Ferrandino, Leah G. Davis, Sitharthan Sekar, Thomas A. Longo, Ghalib Jibara, Tracy Han, Ilhan Gokhan, and Judd W. Moul. “Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.” Can J Urol 24, no. 5 (October 2017): 8982–89.
Gopalakrishna, Ajay, Thomas A. Longo, Joseph J. Fantony, Michael R. Harrison, and Brant A. Inman. “Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.” Urol Oncol 35, no. 9 (September 2017): 540.e1-540.e6. https://doi.org/10.1016/j.urolonc.2017.04.016.
Tsivian, Efrat, Matvey Tsivian, Kae Jack Tay, Thomas Longo, Ziv Zukerman, Giuseppe Martorana, Riccardo Schiavina, Eugenio Brunocilla, and Thomas J. Polascik. “Body mass index and the clinicopathological characteristics of clinically localized renal masses-An international retrospective review.” Urol Oncol 35, no. 7 (July 2017): 459.e1-459.e5. https://doi.org/10.1016/j.urolonc.2017.02.004.
Gopalakrishna, Ajay, Joseph J. Fantony, Thomas A. Longo, Richmond Owusu, Wen-Chi Foo, Rajesh Dash, Brian T. Denton, and Brant A. Inman. “Anticipatory Positive Urine Tests for Bladder Cancer.” Ann Surg Oncol 24, no. 6 (June 2017): 1747–53. https://doi.org/10.1245/s10434-016-5763-5.
Inman, Brant A., Thomas A. Longo, Sundhar Ramalingam, and Michael R. Harrison. “Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1886–90. https://doi.org/10.1158/1078-0432.CCR-16-1417.
Fantony, Joseph J., Thomas A. Longo, Ajay Gopalakrishna, Richmond Owusu, Raymond S. Lance, Wen-Chi Foo, Brant A. Inman, and Michael R. Abern. “Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.” Cancer Biomark 18, no. 4 (2017): 381–87. https://doi.org/10.3233/CBM-160261.